Aarti Pharmalabs Ltd

Aarti Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Aarti Pharmalabs Ltd

₹ 519 -2.50%
26 Apr 1:11 p.m.
aartipharmalabs.com BSE: 543748 NSE : AARTIPHARM
About

Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals[1]

Key Points

Business Overview:[1]
Company is a Wholly Owned Subsidiary of Aarti Industries Limited. It develops Active Pharmaceutical Ingredients, New Chemical Entities, API intermediates, Regulatory Starting Materials, Basic Starting Materials, Key Building Blocks, and Xanthine Derivatives for use in clinical testing and commercial production. It also provides stability studies, scale-up and process optimisation, process validations, and commercial manufacturing.
Company has 6 manufacturing plants and 2 R&D centres.

Website BSE NSE
  • Market Cap ₹ 4,699 Cr.
  • Current Price ₹ 519
  • High / Low ₹ 595 / 320
  • Stock P/E 26.5
  • Book Value ₹ 169
  • Dividend Yield 0.38 %
  • ROCE 15.6 %
  • ROE 12.6 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company has reduced debt.

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
365 373 404 359 374 358 356 373
296 294 324 287 297 281 282 285
Operating Profit 68 79 80 73 77 77 74 88
OPM % 19% 21% 20% 20% 21% 21% 21% 24%
3 0 1 0 0 5 0 0
Interest 4 4 6 5 6 4 4 4
Depreciation 12 12 15 15 14 15 16 17
Profit before tax 54 62 61 53 57 62 54 67
Tax % 17% 24% 25% 27% 30% 23% 22% 29%
45 47 46 39 40 48 42 48
EPS in Rs 4.25 4.41 5.26 4.61 5.32
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 TTM
0 941 1,511 1,462
0 761 1,203 1,146
Operating Profit 0 180 309 316
OPM % 19% 20% 22%
0 3 1 5
Interest 0 11 20 18
Depreciation 0 37 56 63
Profit before tax 0 134 233 240
Tax % 20% 26%
0 107 172 178
EPS in Rs 18.95 19.60
Dividend Payout % 0% 11%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -3%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 1%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 46%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 13%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 0 0 45 45
Reserves -0 1,284 1,393 1,483
0 327 208 217
0 215 317 333
Total Liabilities 0 1,827 1,963 2,078
0 701 848 928
CWIP 0 187 102 89
Investments 0 40 43 43
0 898 970 1,018
Total Assets 0 1,827 1,963 2,078

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023
0 -65 229
0 -134 -116
0 255 -157
Net Cash Flow 0 56 -43

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Mar 2022 Mar 2023
Debtor Days 118 87
Inventory Days 359 280
Days Payable 106 114
Cash Conversion Cycle 371 253
Working Capital Days 263 168
ROCE % 18% 16%

Shareholding Pattern

Numbers in percentages

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
45.98% 45.98% 46.30% 46.46% 46.46%
7.69% 7.43% 8.45% 8.17% 8.33%
13.68% 10.65% 10.51% 9.91% 9.97%
0.01% 0.01% 0.01% 0.01% 0.01%
32.64% 35.92% 34.73% 35.45% 35.24%
No. of Shareholders 2,76,6642,58,2392,26,2862,15,7962,04,122

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls